RE:Fast Track + PR (CR) = Accelerated ApprovalThe possibility of having an accelerated approval granted on the basis of the Phase 2 Goblet study results in pancreatic cancer is what I would strongly urge ONCY to pursue with the FDA - which would subsequently be followed up with a post-marketing confirmatory study in 2023. Other Big Pharma companies have been granted similar approvals for their I/O products on lesser results.
ONCY is currently talking about a registration study in 2023.